RM-1929 comprises IR700 conjugated with cetuximab, an antibody targeting epidermal growth factor receptor (EGFR), which is well-established to be overexpressed in 80–90% of HNSCC tumors [30, 31]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.